Litcius/Paper detail

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Luis Paz‐Ares, Alexander I. Spira, David Raben, David Planchard, Byoung Chul Cho, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Rina Hui, S. Murakami, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, A-M. Boothman, Helen Broadhurst, Catherine Wadsworth, P. Dennis, Scott Antonia, Corinne Faivre‐Finn

2020Annals of Oncology224 citationsDOIOpen Access PDF

Topics & Concepts

DurvalumabMedicineOncologyStage (stratigraphy)Internal medicineLung cancerCancerImmunotherapyNivolumabPaleontologyBiologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsRadiomics and Machine Learning in Medical Imaging
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial | Litcius